Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease

Journal of Neuroscience

Volumn 24, Issue 29, 2004, Pages 6457-6465

  Fonseca, Maria Isabel ^a   Zhou, Jun ^a   Botto, Marina ^b   Tenner, Andrea J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; C1q; Complement; Inflammation; Neuropathology; Transgenic models

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; COMPLEMENT COMPONENT C1Q;

ALZHEIMER DISEASE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DEGENERATIVE DISEASE; FRONTAL CORTEX; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MOUSE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; SENILE PLAQUE; TRANSGENE; TRANSGENIC MOUSE;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BLOTTING, WESTERN; COMPLEMENT C1Q; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEUROGLIA; SENILE PLAQUES;

EID: 3242766671     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0901-04.2004     Document Type: Article

References (70)

1. Afagh A, Cummings BJ, Cribbs DH, Cotman CW, Tenner AJ (1996) Localization and cell association of C1q in Alzheimer's disease brain. Exp Neurol 138:22-32.
2. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21:383-421.
3. Apelt J, Schliebs R (2001) Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res 894:21-30.
4. AsheKH (2001) Learning and memory in transgenic: mice modeling Alzheimer's disease. Learn Mem 8:301-308.
5. Bartoo GT, Nochlin D, Chang D, Kim Y, Sumi SM (1997) The mean A beta load in the hippocampus correlates with duration and severity of dementia in subgroups of Alzheimer disease. J Neuropathol Exp Neurol 56:531-540.
6. Benveniste EN, Nguyen VT, O'Keefe GM (2001) Immunological aspects of microglia: relevance to Alzheimer's disease. Neurochem Int 39:381-391.
7. Bornemann KD, Wiederhold KH, Pauli C, Ermini F, Stalder M, Schnell L, Sommer B, Jucker M, Staufenbiel M (2001) Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am J Pathol 158:63-73.
8. Botto M, Dell'agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, Loos M, Pandolfi PP, Walport MJ (1998) Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 19:56-59.
9. Boyett KW, DiCarlo G, Jantzen PT, Jackson J, O'Leary C, Wilcock D, Morgan D, Gordon MN (2003) Increased fibrillar beta-amyloid in response to human C1q injections into hippocampus and cortex of APP+PS1 transgenic mice. Neurochem Res 28:83-93.
10. Brazil MI, Chung H, Maxfield FR (2000) Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia. J Biol Chem 275:16941-16947.
11. Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, Staufenbiel M, Sommer B, Jucker M (1998) Neuron loss in APP transgenic mice. Nature 395:755-756.
12. Chauhan NB, Siegel GJ (2002) Reversal of amyloid beta toxicity in Alzheimer's disease model Tg2576 by intraventricular anti-amyloid beta antibody. J Neurosci Res 69:10-23.
13. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, Turner S, Lozza G, Grilli M, Kunicki S, Morissette C, Paquette J, Gervais F, Bergeron C, Fraser PE, Carlson GA, et al. (2001) Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 276:21562-21570.
14. Cotman CW, Tenner AJ, Cummings BJ (1996) β-Amyloid converts an acute phase injury response to chronic injury responses. Neurobiol Aging 17:723-731.
15. Cremer H, Chazal G, Carleton A, Goridis C, Vincent JD, Lledo PM (1998) Long-term but not short-term plasticity at mossy fiber synapses is impaired in neural cell adhesion molecule-deficient mice. Proc Natl Acad Sci USA 95:13242-13247.
16. Cummings BJ, Head E, Afagh AJ, Milgram NW, Cotman CW (1996a) Beta-amyloid accumulation correlates with cognitive dysfunction in the aged canine. Neurobiol Learn Mem 66:11-23.
17. Cummings BJ, Pike CJ, Shankle R, Cotman CW (1996b) Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging 17:921-933.
18. Dietzschold B, Schwaeble W, Schäfer MKH, Hooper DC, Zehng YM, Petry F, Sheng H, Fink T, Loos M, Koprowski H, Weihe E (1995) Expression of C1q, a subcomponent of the rat complement system, is dramatically enhanced in brains of rats with either Borna disease or experimental allergic encephalomyelitis. J Neurol Sci 130:11-16.
19. Eikelenboom P, Hack CE, Rozemuller JM, Stam FC (1989) Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch B Cell Pathol 56:259-262.
20. Fonseca MI, Head E, Velazquez P, Cotman CW, Tenner AJ (1999) The presence of isoaspartic acid in β-amyloid plaques indicates plaque age. Exp Neurol 157:277-288.
21. Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, Cole GM (1998) Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 152:307-317.
22. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373:523-527.
23. Gasque P, Singhrao SK, Neal JW, Gotze O, Morgan BP (1997) Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol 150:31-41.
24. Goldsmith SK, Wals P, Rozovsky I, Morgan TE, Finch CE (1997) Kainicacid and decorticating lesions stimulate the synthesis of C1q protein in adult rat brain. J Neurochem 68:2046-2052.
25. Gomez-Isla T, Price JL, McKeel Jr DW, Morris JC, Growdon JH, Hyman BT (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 16:4491-4500.
26. Henson PM (1971) Interaction of cells with immune complexes: adherence, release of constituents, and tissue injury. J Exp Med 134:114s-135s.
27. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4:97-100.
28. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L (1999) Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 96:3228-3233.
29. Hsiao KK, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Ab elevations, and amyloid plaques in transgenic mice. Science 274:99-102.
30. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT (1997a) APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 56:965-973.
31. Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT (1997b) Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 17:7053-7059.
32. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D (1989) Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 24:173-182.
33. Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, Gordon MN (2002) Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 22:2246-2254.
34. Jiang H, Burdick D, Glabe CG, Cotman CW, Tenner AJ (1994) β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J Immunol 152:5050-5059.
35. Johnson SA, Lampert-Etchells M, Pasinetti GM, Rozovsky I, Finch C (1992) Complement mRNA in the mammalian brain: responses to Alzheimer's disease and experimental brain lesioning. Neurobiol Aging 13:641-648.
36. KorbLC, Abearn JM (1997) C1q binding directly and specifically to surface blebs of apoptotic human keratinocytes. J Immunol 158:4525-4528.
37. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20:5709-5714.
38. Masliah E, Mallory M, Hansen L, DeTeresa R, Alford M, Terry R (1994) Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci Lett 174:67-72.
39. Matsuoka Y, Picciano M, Malester B, LaFrancois J, Zehr C, Daeschner JM, Olschowka JA, Fonseca MI, O'Banion MK, Tenner AJ, Lemere CA, Duff K (2001) Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am J Pathol 158:1345-1354.
40. McGeer EG, McGeer PL (1998) The importance of inflammatory mechanisms in Alzheimer disease. Exp Gerontol 33:371-378.
41. McGeer PL, McGeer EG (1999) Inflammation of the brain in Alzheimer's disease: implications for therapy. J Leukoc Biol 65:409-415.
42. Morrison JH, Hof PR (1997) Life and death of neurons in the aging brain. Science 278:412-419.
43. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of Aβ 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20:4050-4058.
44. O'Barr S, Cooper NR (2000) The C5a complement activation peptide increases IL-lbeta and IL-6 release from amyloid-beta primed human monocytes: implications for Alzheimer's disease. J Neuroimmunol 109:87-94.
45. Ong GL, Mattes MJ (1989) Mouse strains with typical mammalian levels of complement activity. J Immunol Methods 125:147-158.
46. Pasinetti GM, Tocco G, Sakhi S, Musleh WD, DeSimoni MG, Mascarucci P, Schreiber S, Baudry M, Finch CE (1996) Hereditary deficiencies in complement C5 are associated with intensified neurodegenerative responses that implicate new roles for the C-system in neuronal and astrocytic functions. Neurobiol Dis 3:197-204.
47. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, et al. (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417:254-259.
48. Ramirez-Amaya V, Balderas I, Sandoval J, Escobar ML, Bermudez-Rattoni F (2001) Spatial long-term memory is related to mossy fiber synaptogenesis. J Neurosci 21:7340-7348.
49. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, Lieberburg I (1992) Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 89:10016-10020.
50. Selkoe DJ, Schenk D (2003) Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43:545-584.
51. Shen Y, Li R, McGeer EG, McGeer PL (1997) Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res 769:391-395.
52. Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker M (1999) Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol 154:1673-1684.
53. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94:13287-13292.
54. Takeuchi A, Irizarry MC, Duff K, Saido TC, Hsiao AK, Hasegawa M, Mann DM, Hyman BT, Iwatsubo T (2000) Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol 157:331-339.
55. Tenner AJ (1999) Membrane receptors for soluble defense collagens. Curr Opin Immunol 11:34-42.
56. Tenner AJ (2001) Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events. Neurobiol Aging 22:849-861.
57. Tenner AJ, Webster SD (2001) Complement-mediated injury and inflammation in the pathogenesis of Alzheimer's disease. In: Inflammatory events in neurodegeneration (Bondy SC, Campbell A, eds), pp 119-138. Scottsdale, AZ: Prominent.
58. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572-580.
59. Urbanc B, Cruz L, Le R, Sanders J, Ashe KH, Duff K, Stanley HE, Irizarry MC, Hyman BT (2002) Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc Natl Acad Sci USA 99:13990-13995.
60. van Beek J, Elward K, Gasque P (2003) Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann NY Acad Sci 992:56-71.
61. Velazquez P, Cribbs DH, Poulos TL, Tenner M (1997) Aspartate residue 7 in amyloid β-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. Nat Med 3:77-79.
62. Webster S, O'Barr S, Rogers J (1994) Enhanced aggregation and A structure of amyloid β peptide after coincubation with C1Q. J Neurosci Res 39:448-456.
63. Webster S, Glabe C, Rogers J (1995) Multivalent binding of complement protein C1q to the amyloid β-peptide (Ab) promotes the nucleation phase of Ab aggregation. Biochem Biophys Res Commun 217:869-875.
64. Webster SD, Tenner AJ, Poulos TL, Cribbs DH (1999) Mouse C1q A-chain sequence alters beta-amyloid-induced complement activation. Neurobiol Aging 20:297-304.
65. Webster SD, Yang AJ, Margol L, Garzon-Rodriguez W, Glabe CG, Tenner AJ (2000) Complement component C1q modulates the phagocytic behavior of microglia. Exp Neurol 161:127-138.
66. West MJ, Coleman PD, Flood DG, Troncoso JC (1994) Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 344:769-772.
67. Wyss-Coray T, Mucke L (2002) Inflammation in neurodegenerative disease-a double-edged sword. Neuron 35:419-432.
68. Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, Masliah E (2002) Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci USA 99:10837-10842.
69. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, Citron M, Landreth G (2003) Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23:7504-7509.
70. Yao J, HarvathL, Gilbert DL, Colton CA (1990) Chemotaxis by a CNS macrophage, the microglia. J Neurosci Res 27:36-42.